Please login to the form below

Not currently logged in
Email:
Password:

Sanofi’s Lantus follow-up nears European approval

CHMP backing for Toujeo follows hot on the heels of its US approval by the FDA

Sanofi 

Sanofi's new insulin Toujeo is just months away from a European approval as the CHMP has recommended the drug for use across the continent. 

Once-daily Toujeo (insulin glargine [rDNA origin]) is a next generation version of Sanofi's blockbuster insulin Lantus, which has been bringing in more than $8bn a year for the firm.

But patents for Lantus are set to fall across key markets later this year, and rival big pharma firm Lilly is poised to release a biosimilar version of the treatment, which could cut its sales - although launch of the copycat has been delayed from its original May 2015 date. 

Just how much of a threat the biosimilar will turn out to be remains to be seen, but Toujeo will be a key new treatment for the firm as falling sales of Lantus - and diabetes treatments in general - start to bite.

The CHMP, which is the safety and efficacy arm of the European Medicines Agency, has issued a positive opinion recommending the approval of Toujeo for patients with type 1 diabetes, as well as type 2 diabetes for those who have failed on oral antidiabetics.

Pierre Chancel, senior VP global diabetes at Sanofi, said: “This CHMP opinion is another step forward to make Toujeo available to people living with diabetes who are currently not at their glycemic target, or are about to start insulin therapy. 

“We are confident that we can soon add this new treatment option to our portfolio to help patients reach their blood sugar goals.” The drug was also approved just last week by the FDA

Analysts are warning that the drug will now face a pricing war with its own product, as well as any biosimilars and other new insulin products from rivals such as Novo Nordisk. 

Sanofi has however made no secret of the fact that it will try to aggressively switch patients from Lantus to Toujeo - even if that means pricing the drug lower than it may like. 

In fact its forecasts of even a slight growth in its diabetes franchise this year relies on that switch happening on a fairly major scale.

How Toujeo fares will be a major challenge for the new chief executive Olivier Brandicourt when he takes the helm in April - the same month the European Commission should give the final approval for the drug.

Article by
Ben Adams

2nd March 2015

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

Deep 6 AI: the smart software breathing new life into clinical trials
Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....
COVID-proof: How Teams are Creating Launch Intensity thru Adversity
Now that the game has changed, how are marketers shifting their launch behaviour? We've identified 5 common observations from effective teams....
5 ways that lockdowns and restrictions could be affecting our allergies
Over this last year, lockdowns and restrictions have led to changes in the day-to-day environments for people across the world. For Allergy Awareness week, we wanted to explore some of...